Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506922 | 0.85 | TNKS2 (0.57) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL28625881 | 0.85 | TNKS2 (0.57) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL30683790 | 0.85 | SMN1; SMN2 (0.58) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL1444438 | 0.85 | ALDH1A1 (0.57) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL29155427 | 0.85 | SMN1; SMN2 (0.58) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL21247061 | 0.85 | HSD17B10 (0.57) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL20681467 | 0.81 | TNKS2 (0.60) | TNKS2HSD17B10ALDH1A1MAPTDRD4 | |
| SCHEMBL21261501 | 0.81 | CYP19A1 (0.46) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL12946628 | 0.81 | CYP19A1 (0.46) | TNKS2HTR2AHTR2CHTR2BPARP1 | |
| SCHEMBL22769969 | 0.81 | PARP1 (0.51) | TNKS2HTR2AHTR2CHTR2BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56018920-A | — | — | None | — | — | JP | disclosed |
| CN-116546990-B | CD73 inhibitor and pharmaceutical application thereof | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| CN-119955090-A | Polyetherimide and preparation method thereof | 大连理工大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-119955090-A | Polyetherimide and preparation method thereof | 大连理工大学 | 2025-05-09 | — | — | CN | disclosed |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | INSTITUTE FOR BASIC SCIENCE (KR) | 2024-06-04 | — | — | US | disclosed |
| WO-2024061340-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-03-28 | — | — | WO | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2345411-A1 | Heterocyclic aspartyl protease inhibitors, preparation and use thereof | Schering Corporation (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| US-20080176868-A1 | pyrrole/pyrimidine-2-imine fused ring derivatives; aspartyl proteases, beta-secretase inhibitor; cardiovascular diseases, cognitive and neurodegenerative diseases such as Alzheimer's, Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes | SCHERING CORPORATION | 2008-07-24 | — | — | US | disclosed |
| US-20080176868-A1 | pyrrole/pyrimidine-2-imine fused ring derivatives; aspartyl proteases, beta-secretase inhibitor; cardiovascular diseases, cognitive and neurodegenerative diseases such as Alzheimer's, Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes | SCHERING CORPORATION | 2008-07-24 | — | — | US | disclosed |
| WO-2006138265-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS, PREPARATION AND USE THEREOF | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-1996036611-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
| EP-0051215-B1 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF 3-ARYL-3-HYDROXY-PHTHALIMIDINES | USV PHARMACEUTICAL CORPORATION (US) | 1987-03-18 | — | — | EP | disclosed |
| JP-S5618920-A | ANTI-INFALMMATORY CONTAINING 3-PHENYLISOINDOLIN-1-ONE DERIVATIVE AS THE EFFECTIVE COMPONENT | MITSUBISHI CHEM IND LTD | 1981-02-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | TNKS2 1401/4885HTR2A 1695/4885HTR2C 1873/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | TNKS2 354/4885HTR2A 2065/4885HTR2C 2278/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | TNKS2 2062/4885HTR2A 4004/4885HTR2C 3733/4885 |
| US-11998901-B2 | Metal complex, method for producing same, and method for producing gamma-lactam compound using same | COASY, NOTUM, MRPL21 | TNKS2 3114/4885HTR2A 4805/4885HTR2C 4841/4885 |
| US-20080176868-A1 | pyrrole/pyrimidine-2-imine fused ring derivatives; aspartyl proteases, beta-secretase inhibitor; cardiovascular diseases, cognitive and neurodegenerative diseases such as Alzheimer's, Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes | BACE1, CTSL, CPN1 | TNKS2 2659/4885HTR2A 3914/4885HTR2C 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.